Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
Johnson & Johnson (NYSE:JNJ) announced groundbreaking long-term data from the DanGer Shock randomized controlled trial for its Impella CP heart pump, published in The New England Journal of Medicine and presented at the European Society of Cardiology Congress.
The study demonstrated that Impella CP achieved an absolute mortality reduction of 16.3% over 10 years compared to standard care, with patients gaining an average of 600 additional days of life. This improvement surpasses the initial 6-month data, which showed a 12.7% reduction in mortality.
The trial, which enrolled 360 participants across 14 sites in Denmark, Germany, and the UK, led to the American College of Cardiology and American Heart Association upgrading Impella to a class 2a guideline recommendation. This marks Impella CP as the first mechanical circulatory support device proven to provide both short-term and long-term survival benefits in STEMI-related cardiogenic shock patients.
Johnson & Johnson's (NYSE:JNJ) Biosense Webster unit has been hit with a permanent injunction by the U.S. District Court for Central California following antitrust violations. The ruling follows a jury verdict that awarded $442 million in damages to Innovative Health, LLC.
The court order prohibits BSW from several anti-competitive practices, including: tying clinical support to exclusive device purchases, discriminating in service provision, implementing anti-reprocessing technologies, and hoarding used catheters. The five-year injunction aims to protect hospitals' access to FDA-regulated reprocessed cardiac catheters, promoting cost savings and environmental sustainability.
Johnson & Johnson (NYSE: JNJ) announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will engage in a Fireside Chat on September 10th, 2025, at 11:30 a.m. Eastern Time.
Investors can access the live audio webcast through JNJ's Investor Relations website. An archived version will be available approximately 48 hours after the presentation.
A Boston jury has awarded $42.6 million to Paul and Kathryn Lovell in a landmark lawsuit against Johnson & Johnson (NYSE:JNJ), marking the largest mesothelioma verdict in Massachusetts history. The case centered on Mr. Lovell's mesothelioma diagnosis, which was linked to asbestos contamination in J&J's baby powder products.
During the two-week trial, attorneys from Dean Omar Branham Shirley presented evidence showing J&J had knowingly concealed health risks associated with their talc products for decades. Internal documents revealed the company's awareness of asbestos contamination, failure to adopt safer alternatives, and manipulation of scientific testing methods. The jury found J&J guilty of negligence and breach of warranty.
[]Johnson & Johnson (NYSE:JNJ) has launched the VIRTUGUIDE™ System, an AI-powered solution for bunion surgery that received FDA 510(k) clearance earlier this year. The system, designed for Lapidus procedures, uses pre-operative planning software developed with PeekMed® to create personalized surgical recommendations.
Early adopters report 30-minute reductions in surgical time compared to traditional techniques. The technology addresses a significant medical need, as bunions affect approximately one-third of U.S. adults. The VIRTUGUIDE™ System joins J&J's VELYS™ Enabling Tech solutions portfolio, aiming to streamline surgical procedures and improve accuracy through patient-matched instrumentation.
Johnson & Johnson (NYSE:JNJ) has submitted a supplemental Biologics License Application (sBLA) to the FDA for TREMFYA® (guselkumab) seeking to include new evidence of joint structural damage inhibition in active psoriatic arthritis (PsA) patients.
The submission is supported by the Phase 3b APEX study, which achieved its primary endpoint of reducing joint symptoms (ACR20) and secondary endpoint of inhibiting structural damage progression at 24 weeks. TREMFYA® would become the first and only IL-23 inhibitor proven to both control symptoms and significantly inhibit joint damage progression in active PsA.
As a dual-acting monoclonal antibody, TREMFYA® uniquely blocks IL-23 while binding to CD64, demonstrating a well-established safety profile in the study.
Johnson & Johnson (NYSE: JNJ) announced its participation in the upcoming 2025 Wells Fargo Healthcare Conference. The company's management will engage in a Fireside Chat on September 3rd, 2025, at 11:50 a.m. Eastern Time.
Investors can access the live audio webcast through JNJ's Investor Relations website. An archived version will be available approximately 48 hours after the presentation.
Johnson & Johnson (NYSE:JNJ) will present significant advancements in Alzheimer's disease research at the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025, in Toronto. The company will showcase 12 research abstracts focusing on tau's impact on brain function in early Alzheimer's and the predictive capabilities of plasma biomarker pTau217.
A key highlight includes new findings from the Global Neurodegeneration Proteomics Consortium (GNPC), a partnership between J&J and Gates Ventures, representing the world's largest neurodegenerative disease proteomics resource. The research spans various areas, including tau PET imaging, CSF proteomics, plasma biomarkers, and AI-based diagnostic approaches.
Johnson & Johnson (NYSE:JNJ) has submitted a New Drug Application (NDA) to the FDA for icotrokinra, a first-in-class targeted oral peptide for treating moderate to severe plaque psoriasis in adults and patients 12+ years old. The submission includes data from four Phase 3 studies (ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 & 2) where icotrokinra met all primary endpoints.
The drug demonstrated superior efficacy to deucravacitinib and showed promising results in difficult-to-treat areas. Safety data revealed similar adverse events between icotrokinra (49.1%) and placebo (51.9%). The company has also initiated ICONIC-ASCEND, the first head-to-head study comparing an oral pill (icotrokinra) to an injectable biologic (ustekinumab).
Johnson & Johnson (NYSE: JNJ) announced that the FDA has granted Priority Review for TAR-200, an innovative intravesical drug releasing system for treating high-risk non-muscle invasive bladder cancer (HR-NMIBC) in patients who are unresponsive to BCG therapy.
The Phase 2b SunRISe-1 study demonstrated impressive results with an 82.4% complete response rate, and 52.9% of patients remaining cancer-free for at least one year. TAR-200 represents the first significant innovation in bladder cancer drug delivery in over 40 years, providing sustained local treatment delivery over three weeks per cycle.
The treatment can be administered in an outpatient setting in under five minutes, requiring no general anesthesia or additional monitoring.